10-Q: Shattuck Labs Secures $46M, Extends Runway to 2029

Shattuck Labs reports reduced Q2 2025 net loss and R&D expenses, secures a significant private placement of up to $103 million, and plans to initiate Phase 1 clinical trials for its lead candidate SL-325.

Summary

• Net loss for the three months ended June 30, 2025, decreased by 42.2% to $12.5 million from $21.6 million in the prior year period.
• Net loss for the six months ended June 30, 2025, decreased by 34.7% to $26.2 million from $40.1 million in the prior year period.
• Research and development (R&D) expenses decreased by 54.9% to $8.7 million for Q2 2025 and by 47.6% to $18.6 million for the six months ended June 30, 2025, primarily due to the discontinuation of SL-172154 and workforce reductions.
• General and administrative (G&A) expenses decreased by 18.4% to $4.4 million for Q2 2025 and by 13.7% to $8.8 million for the six months ended June 30, 2025.
• Collaboration revenue was $0.0 million for both the three and six months ended June 30, 2025, down from $1.6 million and $2.7 million respectively in the prior year, as all obligations under previous agreements were completed in 2024.
• Cash and cash equivalents totaled $50.5 million as of June 30, 2025.
• The company entered into a private placement agreement on August 4, 2025, to issue common stock and pre-funded warrants, expecting upfront gross proceeds of approximately $46 million.
• If all accompanying common stock warrants are exercised, the company could receive an additional $57 million, totaling up to $103 million in gross proceeds.
• The private placement is expected to fund operations into 2029, significantly extending the previous estimate of into 2027.
• The company received a Nasdaq non-compliance notice on August 8, 2025, for failing to meet the minimum $1.00 bid price requirement, with 180 calendar days to regain compliance.

Sentiment

Score: 7

Explanation: The significant capital raise, extending the cash runway to 2029, is a major positive for a pre-revenue biotech, substantially de-risking its financial position. Reduced operating expenses and progress with the lead candidate SL-325 entering Phase 1 are also favorable. While the Nasdaq non-compliance is a concern, the overall financial strengthening and pipeline advancement outweigh this short-term issue.

Positives

• Net loss significantly decreased by 42.2% in Q2 2025 and 34.7% year-to-date, indicating improved financial efficiency.
• Research and development expenses were substantially reduced by 54.9% in Q2 2025 and 47.6% year-to-date, reflecting successful cost management and strategic pipeline focus.
• The company secured a private placement expected to yield approximately $46 million upfront, with potential for an additional $57 million from warrant exercises, providing significant capital.
• The new capital raise is projected to extend the company's cash runway from into 2027 to into 2029, substantially de-risking its financial position.
• SL-325, the lead product candidate for inflammatory bowel disease, is progressing towards a Phase 1 clinical trial initiation in Q3 2025, with promising preclinical data suggesting a favorable safety profile and potential for best-in-class efficacy.
• The company's DR3 targeting approach for SL-325 is designed to avoid immune complex formation and high rates of anti-drug antibody (ADA) responses seen with some TL1A blocking antibodies, potentially offering a better safety profile.
• The One Big Beautiful Bill Act of 2025 (OBBBA) eliminates restrictions on orphan drug exemption from Medicare drug price negotiation, which could positively impact future commercialization of potential orphan drug candidates.

Negatives

• Collaboration revenue dropped to $0.0 million for the three and six months ended June 30, 2025, compared to $1.6 million and $2.7 million in the prior year periods, due to the completion and termination of previous agreements.
• The company has incurred losses and negative cash flows from operations since inception, with an accumulated deficit of $407.9 million as of June 30, 2025.
• Received a Nasdaq non-compliance notice on August 8, 2025, for failing to meet the minimum $1.00 bid price requirement, posing a risk to continued listing.
• Cash and cash equivalents decreased to $50.5 million as of June 30, 2025, from $57.4 million at December 31, 2024, before the impact of the recent private placement.

Risks

• The company will require additional funding to complete product development and commercialization, and such funding may not be available on acceptable terms or at all.
• The recently announced private placement is subject to closing conditions, including FDA clearance of the IND for SL-325, and there is no assurance it will be completed as anticipated.
• The global macroeconomic environment, including inflation, slower growth, and market volatility, could negatively affect future operations.
• The actual probability of success for product candidates is uncertain and may be affected by safety, efficacy, competition, manufacturing capability, and commercial viability.
• The company may obtain unexpected results from nonclinical studies and clinical trials, or may elect to discontinue, delay, or modify them.
• The company is highly dependent on a limited number of contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs), and significant interruptions could adversely affect programs.
• Failure to regain compliance with Nasdaq's minimum bid price rule could lead to delisting, resulting in limited market quotations, reduced liquidity, and decreased ability to raise future financing.
• Current and future laws and regulations, such as the Inflation Reduction Act, could increase the difficulty and cost of obtaining marketing approval and affect product pricing.

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the near term as it advances preclinical and initiates Phase 1 clinical development of SL-325, and potentially other product candidates. It does not anticipate generating significant product revenue until successful development, regulatory approval, and commercialization, which is expected to take several years. Management believes current cash and cash equivalents are sufficient to fund operations into 2027, and with the anticipated proceeds from the recent private placement (up to $103 million), the cash runway is expected to extend into 2029. The company is also evaluating options for its TRIM7 program, including independent financing of a subsidiary or out-licensing.

Management Comments

• Management believes that the company's cash and cash equivalents of $50.5 million as of June 30, 2025, are sufficient to fund projected operations for at least the next twelve months.
• We believe that the underlying biological differences in the expression of DR3 and TL1A, and the design characteristics of SL-325, may allow SL-325 to achieve best-in-class clinical remission rates in patients with IBD due to a more complete and durable blockade of the clinically validated DR3/TL1A pathway.
• The lack of toxicity of SL-325 in our recently completed non-human primate (NHP) toxicology study also suggests a potentially favorable clinical safety profile.
• We expect to initiate enrollment in our Phase 1 clinical trial of SL-325 in the third quarter of 2025, and we expect to complete enrollment in the full Phase 1 clinical trial in the second quarter of 2026.
• We expect to receive upfront aggregate gross proceeds of approximately $46 million, before deducting placement agent fees and estimated offering expenses. If all common stock warrants are exercised in full, we could receive additional aggregate gross proceeds of approximately $57 million.
• We believe that our cash and cash equivalents as of June 30, 2025, are sufficient to fund projected operations into 2027. This does not include the anticipated proceeds from the Private Placement. The total anticipated gross proceeds from the Private Placement of up to approximately $103 million, which includes the potential proceeds to be received upon the full exercise of the common stock warrants, combined with current cash and cash equivalents, are expected to fund operations into 2029.

Industry Context

The company operates in the biotechnology sector, specifically focusing on inflammatory and immune-mediated diseases, a field with significant unmet medical needs and ongoing research into novel therapeutic pathways. Its lead program, SL-325, targets the DR3/TL1A pathway, which is clinically validated for inflammatory bowel disease (IBD). The company highlights its differentiated approach by targeting DR3 directly, aiming for a more complete and durable blockade compared to existing or developing TL1A blocking antibodies, which have shown issues with immune complex formation and immunogenicity (e.g., AMG966). The industry trend towards multi-pathway blockade for complex diseases like IBD is acknowledged, with the company developing DR3 bispecific antibodies. The recent enactment of the One Big Beautiful Bill Act of 2025, which broadens the orphan drug exemption from Medicare drug price negotiation, reflects a favorable regulatory development for biotech companies developing treatments for rare diseases.

Comparison to Industry Standards

• SL-325's preclinical studies demonstrated better TL1A binding blockade compared to sequence equivalents of leading TL1A blocking antibodies, suggesting a potentially superior mechanism of action.
• The design of SL-325 to lack Fc gamma receptor binding function and its lack of evidence for antibody dependent cellular cytotoxicity or cellular phagocytosis aims to provide a derisked safety profile, contrasting with immunogenicity issues observed in some bispecific antibodies like AMG966 (a TL1A and TNF blocking antibody that was discontinued due to high-titer neutralizing ADA responses).
• The company's focus on DR3 as a membrane-restricted target is intended to avoid immune complex formation, a known issue with soluble TL1A blocking antibodies that can lead to immunogenicity.
• The projected cash runway extension to 2029, following the private placement, positions the company with a longer financial lifeline compared to many early-stage biotechs that often face more frequent capital needs.

Management Changes

Legal Proceedings

• As of June 30, 2025, the company was not aware of any existing, pending, or threatened legal actions that would have a material impact on its financial position, results of operations, or cash flows.

Stakeholder Impact

• Shareholders: Potential dilution from the private placement, but also significant de-risking of the company's financial runway. Nasdaq non-compliance poses a risk to share liquidity and demand.
• Employees: Workforce reductions in 2024 have impacted compensation expenses, but the extended cash runway provides greater job security for remaining personnel.
• Customers (future): The advancement of SL-325 towards clinical trials offers potential future treatments for inflammatory bowel disease patients.
• Creditors: Improved liquidity and extended cash runway reduce credit risk.
• Suppliers/CDMOs/CROs: Continued reliance on a limited number of third-party providers for R&D and manufacturing, indicating ongoing business for these partners.

Next Steps

• Initiate enrollment in the Phase 1 clinical trial of SL-325 in the third quarter of 2025.
• Complete enrollment in the full Phase 1 clinical trial of SL-325 in the second quarter of 2026.
• Nominate a lead bispecific candidate from the preclinical pipeline in 2025.
• Actively monitor the closing bid price of common stock and evaluate options to regain compliance with Nasdaq's minimum bid price rule by February 4, 2026.
• File a new Registration Statement on Form S-3 to enable future sales under the ATM Facility.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements and disclosures.

Key Dates

Recommendation

The company has significantly de-risked its financial position through a substantial private placement, extending its cash runway to 2029. This provides critical funding for the advancement of its lead candidate, SL-325, into Phase 1 clinical trials. While the company is still pre-revenue and faces a Nasdaq compliance issue, the extended liquidity and focused pipeline development represent a strong positive catalyst for long-term investors willing to accept the inherent risks of biotech development. The reduced burn rate also indicates improved operational efficiency.

Keywords

Biotechnology, Inflammatory Bowel Disease, IBD, SL-325, DR3 antagonist, Clinical trials, SEC filing, 10-Q, Private placement, Cash runway, Nasdaq compliance, Drug development, Biopharma, Immunology